Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
      • All Events
      • COVID-19
      • Diabetes
      • Immunology
      • Neuroscience
      • Obesity
      • Oncology
      • Cardiovascular
      • COVID-19
      • Diabetes
      • Immunology
      • Men's Health
      • Neuroscience
      • Oncology
  • Medical Education
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

Diabetes Journal Publications

This page includes links to Lilly sponsored clinical trials that have been published in peer reviewed journals over the last 3 years. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please Contact Lilly services below for further assistance.

Basaglar

Full Prescribing Information

LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels

Published Date: September 21, 2017
Publication Link

No Publications.

Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self-titrating insulin glargine U-100

Published Date: August 2, 2019
Publication Link

Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study

Published Date: May 22, 2019
Publication Link

Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)

Published Date: January 2, 2019
Publication Link

Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2

Published Date: July 23, 2018
Publication Link

Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation

Published Date: May 31, 2018
Publication Link

Characteristics of insulin-Naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials

Published Date: May 8, 2018
Publication Link

Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

Published Date: March 14, 2018
Publication Link

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine

Published Date: March 30, 2017
Publication Link

Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study

Published Date: April 23, 2020
Publication Link

Glucagon

Full Prescribing Information

No Publications.

No Publications.

NASAL GLUCAGON DELIVERY IS MORE SUCCESSFUL THAN INJECTABLE DELIVERY: A SIMULATED SEVERE HYPOGLYCEMIA RESCUE

Published Date: April 15, 2020
Publication Link

Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study

Published Date: March 1, 2020
Publication Link

A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting

Published Date: March 22, 2018
Publication Link

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting

Published Date: March 22, 2018
Publication Link

Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial

Published Date: November 19, 2017
Publication Link

Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study

Published Date: May 30, 2017
Publication Link

Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes

Published Date: February 16, 2016
Publication Link

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study

Published Date: December 17, 2015
Publication Link

No Publications.

Humalog

Humalog® U-100 | Full Prescribing Information
Humalog® U-200 | Full Prescribing Information
Humalog® MIX50/50™ | Full Prescribing Information
Humalog® MIX75/25™ | Full Prescribing Information

No Publications.

No Publications.

No Publications.

Insulin exposure mitigates the increase of arterial stiffness in patients with type 2 diabetes and albuminuria: an exploratory analysis

Published Date: May 17, 2019
Publication Link

Fasting experience of patients with Type 2 diabetes mellitus on insulin therapy during Ramadan: VISION Ramadan substudy

Published Date: February 27, 2019
Publication Link

Patterns and trends in insulin initiation and intensification among patients with Type 2 diabetes mellitus in the Middle East and North Africa region

Published Date: January 14, 2019
Publication Link

Relative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post Hoc Analysis of a Phase IV Randomized Trial

Published Date: March 24, 2018
Publication Link

When basal insulin is not enough: successful strategies for insulin intensification in patients with type 2 diabetes mellitus

Published Date: December 15, 2017
Publication Link

CREED study: Hypoglycaemia during Ramadan in individuals with Type 2 diabetes mellitus from three continents

Published Date: July 13, 2017
Publication Link

Simulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic Medications

Published Date: July 3, 2017
Publication Link

Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial

Published Date: May 24, 2017
Publication Link

Humulin

Humulin® R (U-100) | Full Prescribing Information
Humulin® R (U-500) | Full Prescribing Information
Humulin® 70/30 | Full Prescribing Information
Humulin® N U-100 | Full Prescribing Information

No Publications.

No Publications.

Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study.

Published Date: December 22, 2019
Publication Link

No Publications.

Lyumjev

Full Prescribing Information

Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects

Published Date: June 13, 2020
Publication Link

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study

Published Date: May 29, 2020
Publication Link

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial

Published Date: May 29, 2020
Publication Link

Ultra Rapid Lispro Lowers Postprandial Glucose and More Closely Matches Normal Physiological Glucose Response Compared to Other Rapid Insulin Analogs: A Phase 1 Randomized, Crossover Study

Published Date: May 21, 2020
Publication Link

Ultra-Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog® in Japanese patients with type 1 diabetes

Published Date: December 9, 2019
Publication Link

Ultra Rapid Lispro Demonstrates Similar Time in Target Range to Lispro With a Hybrid Closed-Loop System

Published Date: November 25, 2021
Publication Link

Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2

Published Date: 09 March 2021
Publication Link

Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study

Published Date: December 31, 2020
Publication Link

Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D

Published Date:** Online: 2 July 2020, Print: 20 November 2020
Publication Link

Ultra Rapid Lispro Improves Postprandial Glucose Control Compared With Lispro in Patients With Type 1 Diabetes: Results from the 26-Week PRONTO-T1D Study

Published Date: June 15, 2020
Publication Link

Ultra Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Sub-Study

Published Date: May 21, 2020
Publication Link

No Publications.

Mounjaro

Full Prescribing Information

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Published Date: June 08, 2022
Publication Link

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

Published Date: April 22, 2022
Publication Link

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Published Date: March 29, 2021
Publication Link

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

Published Date: February 24, 2022
Publication Link

Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.

Published Date: January 27, 2020
Publication Link

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Published Date: November 17, 2018
Publication Link

Tirzepatide Once Weekly for the Treatment of Obesity.

Published Date: June 5, 2022
Publication Link

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

Published Date: April 22, 2022
Publication Link

Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.

Published Date: April 22, 2022
Publication Link

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

Published Date: November 13, 2021
Publication Link

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.

Published Date: August 14, 2021
Publication Link

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

Published Date: August 5, 2021
Publication Link

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

Published Date: July 10, 2021
Publication Link

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.

Published Date: February 8, 2021
Publication Link

No Publications.

Trulicity

Full Prescribing Information

No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide

Published Date: March 29, 2017
Publication Link

Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion

Published Date: February 17, 2017
Publication Link

Change in HbA1c Across the Baseline HbA1c Range in Type 2 DiabetesPatients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents

Published Date: May 4, 2019
Publication Link

Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme

Published Date: March 30, 2018
Publication Link

Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c

Published Date: August 17, 2017
Publication Link

No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer

Published Date: July 29, 2017
Publication Link

Assessment of PancreasSafety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide

Published Date: March 10, 2017
Publication Link

Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis

Published Date: April 10, 2020
Publication Link

Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c

Published Date: April 3, 2020
Publication Link

Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1

Published Date: March 26, 2020
Publication Link

Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis

Published Date: November 23, 2019
Publication Link

Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial

Published Date: July 31, 2019
Publication Link

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Published Date: July 13, 2019
Publication Link

Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)

Published Date: June 21, 2019
Publication Link

Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study

Published Date: May 18, 2019
Publication Link

Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents

Published Date: May 4, 2019
Publication Link

Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups

Published Date: March 15, 2019
Publication Link

Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)

Published Date: February 14, 2019
Publication Link

Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States

Published Date: February 3, 2019
Publication Link

Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial

Published Date: August 21, 2018
Publication Link

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Published Date: June 14, 2018
Publication Link

Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme

Published Date: March 30, 2018
Publication Link

Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration

Published Date: March 23, 2018
Publication Link

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

Published Date: February 23, 2018
Publication Link

Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes

Published Date: December 20, 2017
Publication Link

Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes

Published Date: September 14, 2017
Publication Link

Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c

Published Date: August 17, 2017
Publication Link

No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer

Published Date: July 29, 2017
Publication Link

Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies

Published Date: June 12, 2017
Publication Link

Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND ) trial on the cardiovascular effects of dulaglutide

Published Date: June 1, 2017
Publication Link

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD -9)

Published Date: April 10, 2017
Publication Link

Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan

Published Date: March 29, 2017
Publication Link

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide

Published Date: March 10, 2017
Publication Link

Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment

Published Date: March 7, 2017
Publication Link

Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents

Published Date: May 4, 2019
Publication Link

Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme

Published Date: March 30, 2018
Publication Link

Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration

Published Date: March 23, 2018
Publication Link

Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c

Published Date: August 17, 2017
Publication Link

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD -9)

Published Date: April 10, 2017
Publication Link

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.15 01/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly